SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Transgene Biotek informs about outcome of board meeting

14 Feb 2022 Evaluate

With reference to letter dated 27th January 2022, Transgene Biotek has informed that at the meeting of the Board of Directors of the Company held on 14th February 2022 the following decisions have been taken: Approved the Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of the Company for the quarter ended 31st December 2021 and approved the Licensing agreement between Transgene Biotek (the company) and NiedlFree Technologies.

The above information is a part of company’s filings submitted to BSE.

Transgene Biotek Share Price

3.10 0.22 (7.64%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 435.70
Indegene 486.80
CMS Info Systems 318.00
JITF Infralogistics 338.00
Sagility 42.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×